Yarrow Bioscience Inc (YARW)
Nasdaq · Healthcare · Biotechnology
$20.30−8.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $189M
- 52-week range
- $16.05 – $46.95
- 52-week change
- +9.70%
Fiscal year to Dec 2025
- Revenue
- $570K (+13.77%)
- Net income
- −$26.5M
- Operating margin
- −5219.1%
- Diluted EPS
- −$0.62
- Free cash flow
- −$33.1M
From the company’s annual report on SEC EDGAR.
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Headquarters: New York, United States · 7 employees · yarrowbioscience.com